Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$121.28 USD
-0.19 (-0.16%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $118.20 -3.08 (-2.54%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Neurocrine Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,032 | 989 | 711 | 801 | 671 |
Receivables | 439 | 350 | 186 | 157 | 127 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 38 | 35 | 31 | 28 | 17 |
Other Current Assets | 98 | 79 | 46 | 30 | 17 |
Total Current Assets | 1,607 | 1,454 | 973 | 1,016 | 831 |
Net Property & Equipment | 71 | 59 | 59 | 45 | 42 |
Investments & Advances | 849 | 402 | 624 | 265 | 300 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 363 | 306 | 315 | 319 | 0 |
Intangibles | 36 | 37 | 0 | 0 | 0 |
Deposits & Other Assets | 50 | 25 | 4 | 6 | 59 |
Total Assets | 3,251 | 2,369 | 2,073 | 1,735 | 1,306 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 170 | 169 | 0 | 0 | 0 |
Accounts Payable | 449 | 348 | 226 | 169 | 141 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 409 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 36 | 21 | 20 | 18 | 15 |
Total Current Liabilities | 655 | 538 | 246 | 187 | 565 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 335 | 318 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 106 | 30 | 12 | 10 | 17 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,019 | 661 | 699 | 609 | 669 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,382 | 2,122 | 2,011 | 1,850 | 1,768 |
Retained Earnings | -157 | -407 | -636 | -725 | -1,133 |
Other Equity | 7 | -8 | -2 | 2 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,232 | 1,708 | 1,374 | 1,126 | 637 |
Total Liabilities & Shareholder's Equity | 3,251 | 2,369 | 2,073 | 1,735 | 1,306 |
Total Common Equity | 2,232 | 1,708 | 1,374 | 1,126 | 637 |
Shares Outstanding | 98.20 | 96.10 | 94.80 | 93.90 | 92.00 |
Book Value Per Share | 22.73 | 17.77 | 14.49 | 11.99 | 6.92 |
Fiscal Year End for Neurocrine Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,039 | 1,211 | 1,032 | 1,095 | 977 |
Receivables | 468 | 451 | 439 | 418 | 388 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 43 | 37 | 38 | 29 | 32 |
Other Current Assets | 120 | 101 | 98 | 108 | 101 |
Total Current Assets | 1,670 | 1,799 | 1,607 | 1,650 | 1,497 |
Net Property & Equipment | 80 | 75 | 71 | 69 | 66 |
Investments & Advances | 781 | 864 | 849 | 588 | 516 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 420 | 378 | 363 | 383 | 379 |
Intangibles | 34 | 34 | 36 | 35 | 37 |
Deposits & Other Assets | 58 | 51 | 50 | 43 | 36 |
Total Assets | 3,305 | 3,472 | 3,251 | 2,848 | 2,613 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 259 | 170 | 170 | 170 |
Accounts Payable | 359 | 417 | 449 | 503 | 392 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 40 | 37 | 36 | 19 | 21 |
Total Current Liabilities | 399 | 713 | 655 | 692 | 583 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 141 | 106 | 69 | 89 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 796 | 1,086 | 1,019 | 846 | 760 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,555 | 2,496 | 2,382 | 2,309 | 2,242 |
Retained Earnings | -49 | -114 | -157 | -305 | -388 |
Other Equity | 3 | 3 | 7 | -2 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,509 | 2,386 | 2,232 | 2,002 | 1,853 |
Total Liabilities & Shareholder's Equity | 3,305 | 3,472 | 3,251 | 2,848 | 2,613 |
Total Common Equity | 2,509 | 2,386 | 2,232 | 2,002 | 1,853 |
Shares Outstanding | 100.90 | 100.60 | 98.20 | 98.20 | 97.60 |
Book Value Per Share | 24.87 | 23.72 | 22.73 | 20.39 | 18.99 |